Andecaliximab
As of the edition of 20 October 2026, Andecaliximab is an antibody: in active development; acts on MMP9.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2029
- Kind
- Antibody
- Registered trials
- 14, 5 stopped early
- Disease areas
- Digestive system; Cancer; Bones, joints and muscles; Lungs and airways; Skin and connective tissue; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Andecaliximab.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| MMP9 | Matrix metalloproteinase-9 | P14780 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 6 | 5 | 0 | 1 |
| Phase 2 | 5 | 1 | 1 | 3 |
| Phase 3 | 3 | 1 | 1 | 1 |
| All trials | 14 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Gilead Sciences | Lead sponsor of trials | 2013 to now |
| Ashibio | Lead sponsor of trials | 2024 to now |